2013

1. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

   British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572